CBD

U.S.: Senators Tell Federal Agencies To Remove Barriers To Medical Marijuana Research

CoryBookerAndKirstenGillibrand[MarkWilson]

FDA and NIDA officials express support for ending NIDA’s DEA-mandated monopoly on marijuana available for research purposes

By Steve Elliott
Hemp News

At a Wednesday hearing, Senators Cory Booker and Kirsten Gillibrand pressed federal officials to eliminate political barriers that are preventing research on the potential medical benefits of marijuana. The hearing, “Cannabidiol: Barriers to Research and Potential Medical Benefits,” was held by the Senate Caucus on International Narcotics Control.

Officials from the National Institute on Drug Abuse (NIDA) and the Food and Drug Administration (FDA) echoed the Senators’ concerns and expressed support for removing barriers to research that have been created by the Drug Enforcement Administration (DEA).

NIDA has a DEA-mandated monopoly on the supply of marijuana available for research purposes, which is grown at the University of Mississippi. Researchers have repeatedly criticized the DEA for refusing to license additional marijuana producers, which they say is preventing the study of marijuana’s medical benefits and the development of marijuana-based medicines.

They have also criticized the poor quality and low potency of the scant marijuana that is currently available, which they say further hinders meaningful research. A DEA administrative law judge ruled that licensing additional producers would be in the public interest, but the DEA has refused to follow the non-binding ruling.

U.S.: Mary's Nutritionals CBD Products Available For Nationwide Shipping

MarysJournal[MarysNutritionals]

CBD Sourced from High-Quality, Colorado-Grown Organic Hemp Flowers

Mary's Nutritionals on Tuesday announced that its Elite CBD™ products, including gels, compounds, Muscle Freeze and Remedy Oil, are now available for nationwide online purchase and shipping via marysnutritionals.com.

Mary's Elite CBD™ is derived from Elite Botanicals' Colorado-grown, 100 percent organic and natural industrial hemp cannabis plants.

"Mary's is committed to providing products made from plants selected for their optimal cannabinoid content so we can provide the best value to our customers," said Nicole Smith, Mary's Nutritionals CEO. "Plants with a higher concentration of quality CBD deliver more bang for the buck."

Elite Botanicals is a family-run organic hemp farm that produces Elite CBD plants in full compliance with Colorado Department of Agriculture, the 2014 Farm Bill and the pending Industrial Hemp Farming Act of 2015.

"We receive calls and emails every day from individuals across the country looking for high-quality CBD options," said Smith. "With Elite Botanicals' unique industrial hemp, we are now able to create new products with the benefits of whole plant-derived CBD that can be distributed to everyone in need—regardless of where they live."

Product Details

• Mary's Elite CBD™ Gel Pen is the perfect resource for quick, discreet delivery of CBD. Mary's proprietary dispenser pen contains 50-2mg doses of CBD Gel. Users apply it to the wrist, ankle, temples, or any other veinous area. Contains 100mg CBD.

U.S.: Senate Members To Investigate Barriers To Researching Marijuana Extract CBD

USSenateFlag

The U.S. Senate Caucus on International Narcotics Control will hold a hearing Wednesday morning on cannabidiol (CBD), a component of marijuana being used in the treatment of seizure disorders and other medical conditions, and federal obstacles to studying its efficacy.

The hearing, “Cannabidiol: Barriers to Research and Potential Medical Benefits” will be led by Sens. Charles Grassley (R-IA) and Diane Feinstein (D-CA), who have long been opponents of efforts to reform federal marijuana laws.

Sens. Cory Booker (D-NJ) and Kirsten Gillibrand (D-NY) have been invited to participate. They are sponsors of the CARERS Act, bipartisan legislation that would resolve the tension between state and federal marijuana laws.

The hearing is expected to focus on the use of CBD in the treatment of seizure disorders rather than whole-plant medical marijuana and the many other medical conditions for which doctors frequently recommend it. It is also expected to focus on federally regulated distribution channels rather than state-regulated medical marijuana providers.

WHAT: Hearing on CBD research and efficacy

WHEN: Wednesday, June 24, 9:30 a.m. ET

WHERE: Dirksen Senate Office Building, Room 226, Washington, D.C.

WHO: Dr. John Brad Ingram, child neurologist, University of Mississippi
Dr. Tom Minahan, emergency physician and parent of child with seizure disorder
Joseph Rannazzisi, deputy assistant administrator, Office of Diversion Control, Drug Enforcement Administration (DEA)
Dr. Kevin Sabet, anti-marijuana activist, Project SAM

U.S.: Marijuana-Derived CBD Products Introduced For Dogs, Cats, Horses

MarysPetsLouieCat

Denver, Colorado-based Mary's Pets on Thursday announced the availability of pet-care products made from American cannabidiol (CBD).

"More and more humans are benefitting from cannabinoid medicine. Shouldn't our furry companions also have access to natural relief?" said Nicole Smith, CEO, Mary's Pets, manufacturer of pet-care CBD supplements made from Colorado-grown hemp.

Smith is also CEO and owner of Mary's Nutritionals, a CBD supplement company using the same hemp-based cannabinoids for people, and Mary's Medicinals, a cannabis company best known for its transdermal patch.

"We've combined our award-winning research and development capabilities and experiences designing medical cannabis products for humans with the latest veterinary science to offer the first transdermal CBD product for our feline, canine and equine friends," Smith said.

The premier offering in the Mary's Pets line is Mary's CBD Gel, a clinically formulated, precisely dosed, transdermal lotion designed to relieve symptoms in mammals of all types.

"Everyone gets sick and feels pain, our pets included," said Noel Palmer, Ph.D., chief scientist, Mary's Pets. "For most animals, CBD can be effectively used as an anti-inflammatory agent, pain-relieving compound and anti-epileptic — just as with humans."

Mary's Pets Gel is enriched with hemp-derived CBD organically grown by Elite Botanicals in northern Colorado. CBD is a non-psychoactive compound that is reported to have anti-convulsive, anti-anxiety, anti-psychotic, anti-nausea, anti-rheumatoid arthritic and sedative properties.

Colorado: 'First Ever' Extended Release Cannabis Capsule Released

WanaCapsExtendedReleaseCapsules

Wana Products on Tuesday announced the launch of WanaCaps XR, a family of extended release cannabis capsules that provide medicinal benefits for up to 12 hours.

Wana Products partnered with Cannabics Pharmaceuticals Inc., a United States-based Drug Development Company with research and development in Israel, that developed the proprietary technology behind the extended release formulation.

WanaCaps XR will be offered in three different formulations: capsules with a 10:1 CBD to THC ratio (WanaCaps XR High CBD Capsules), a 10:1 THC to CBD ratio (WanaCaps XR High THC Capsules), and a balanced formulation with 1:1 THC:CBD ratio (WanaCaps XR THC/CBD Balanced Capsules).

“WanaCaps XR represents the next generation in the evolution of marijuana for the medical community,” said Nancy Whiteman, co-owner of Wana Products. “The extended release formulation enables patients to dose once or twice daily so they can get on with their lives without the constant need to be thinking about re-dosing. Additionally, WanaCaps XR are formulated to be highly bio-available so patients feel the therapeutic impact quickly.”

“The new capsules also address one of the major concerns of cannabis patients, which is that the initial high peak of cannabinoid activity soon after administration which can cause uncomfortable side effects such as disorientation and dizziness,” Whiteman said. “Instead, with WanaCaps XR, patients experience a long-lasting, stable effect for up to 10 hours without the ups and downs. Overall, it’s just a much better experience for patients.”

Israel: Researchers Eliminate 60% of Myeloma Cells With Cannabis-Based Treatments

OneWorldCannabis(logo)

As the possibilities for cannabis-based treatments continue to make headlines in the medical world, One World Cannabis, a medical-cannabis research company, has announced that the initial results of its landmark study on treating multiple myeloma with cannabis-based solutions were extremely promising. After a series of tests using cannabis-based treatments, researchers were able to eradicate 60 percent of multiple myeloma cells.

The disease is one of the most deadly hematologic cancers and individuals diagnosed with the disease often have about a 50 percent survival rate.

OWC Pharmaceutical Research Corp. on Wednesday announced that its wholly owned subsidiary, One World Cannabis Ltd., an Israel-based developer of cannabinoid-based therapies targeting a variety of different indications, has received the first basic science study (lab) results on the effect of several combination of cannabidiol (CBD) and tetrahydrocannabinol (THC) on multiple myeloma cell line RPMI8226.

Based on the results, One World Cannabis will submit the clinical trial protocol to the IRB (Helsinki committee). The company expects to receive institutional review board approval for the study within 6-9 weeks.

The OWC multiple myeloma study was done by three repetitive tests on the effect of cannabis extract with various combination ratios of THC/CBD and pure THC and CBD (50 percent concentration). The results present more than 60 percent malignant cell death. More results of pure THC and CBD are under further analysis.

Puerto Rico: Cannabis Treatment Helps 9-Year-Old Boy Speak His First Words

KalelSantiagoWithParentsAbielAndGladys[YahooParenting]

By Steve Elliott
Hemp News

Kalel Santiago of Puerto Rico is just 9 years old, but he hasn't had an easy nine years. At just 10 months old, he was diagnosed with the rare childhood cancer neuroblastoma, and he spent more than two years going through surgery, chemotherapy, and radiation treatments. Then he was diagnosed with severe, non-verbal autism.

"While he was in the hospital, we noticed he didn't speak at all and had some behavior that wasn't right, like hand flapping, and walking on his toes," said Abiel Gomez Santiago, Kalel's father, from their home in Aguada, reports Beth Greenfield at Yahoo Parenting. "But we waited until he was 3 and cancer-free to look at his behavior."

Abiel and his wife Gladys did a crash course in autism. They tried various therapies, and eventually happened upon a treatment that would change their lives: hemp oil, rich in cannabidiol (CBD), which has anecdotally been shown to dramatically ease symptoms of both epilepsy and autism.

They began giving their son twice daily doses of a CBD oral spray, and the results were startling -- Kalel started talking in just two days after a lifetime of silence.

“He surprised us in school by saying the vowels, A-E-I-O-U. It was the first time ever,” Abiel said. “You can’t imagine the emotion we had, hearing Kalel’s voice for the first time. It was amazing.

Florida: Judge Clears Way For Non-Euphoric Medical Marijuana

FloridaFlagMedicalMarijuana(USE)

By Steve Elliott
Hemp News

Florida regulators said they expect to provide access to a strain of non-euphoric marijuana for medical purposes by the end of this year after a Tallahassee judge last week dismissed the final challenge to the long-awaited rule.

The Florida Department of Health is expected to start accepting applications within three weeks from eligible growers within three weeks for the strain of cannabis that is low in THC, the main "high"-inducing component, and high in cannabidiol (CBD), which, like THC, also has medicinal effects, reports Mary Ellen Klas at the Miami Herald.

Growers could start selling to eligible patients who are put on a state-run "compassionate use registry" within months.

"I am one happy legislator," said Rep. Matt Gaetz (R-Shalimar), one of the sponsors of the 2014 bill designed to allow the development and cultivation of the "Charlotte's Web" strain of low-THC cannabis to help patients suffering from epileptic seizures and other ailments. (The clueless legislators passed the law naming a specific strain of low-CBD marijuana, evidently unaware that there are lots of low-CBD medicinal strains, but in the process making the Stanley Brothers -- who control the supply of Charlotte's Web -- very happy.)

South Carolina: Mom Legally Making, Selling Medical Marijuana CBD Extract

PalmettoSynergisticResearch

By Steve Elliott
Hemp News

A mother in South Carolina is manufacturing cannabis oil, legally. The oil is high in cannabidiol (CBD), a non-psychoactive but medicinal component of marijuana that is now legal in the state under S. 839, which allows for consumable hemp products with less than .3 percent of THC.

"I'm building my company here," said Janel Ralph, reports Molly Grantham at WISTV.com. "I think it'll be up and running in maybe six months. But I'm an optimist. I guess I can't say exactly on the timeline."

Janel's company, Palmetto Synergistic Research, will specialize in CBD oil.

Because of the controversy surrounding marijuana, Ralph is keeping her location secret.

"There will be people who would intentionally try to steal it not knowing that it's hemp," she said. "Criminals could hear I'm manufacturing medical marijuana and think they could take it.

"They wouldn't understand that what I'm making has such a low THC, that even if they took they plants they couldn't smoke it or sell it as marijuana," she said. "You can't get high on what I'm making."

Ralph started it all last year because of her five-year-old daughter, Harmony, who has a genetic condition called lissencephaly. Harmony's brain is missing one of her chromosomes, and she has lots of seizures. Multiple pharmaceuticals didn't work.

Texas: House Approves Flawed Medical Marijuana Bill; Will Go To Governor For Signature

TexasMedicalMarijuanaPolicyReform[ProgressTexas]

Bill is intended to allow access to low-THC marijuana extracts for qualifying seizure patients; House fails to pass amendment to fix major problem

The Texas State House on Monday approved a bill 96-34 intended to allow qualifying patients with intractable seizure conditions to access a marijuana extract containing high levels of cannabidiol, or CBD, and only trace levels of THC. SB 339, sponsored by Sen. Kevin Eltife (R-Tyler), is extremely unlikely to provide patients with relief because it requires doctors to engage in conduct that is prohibited by federal law.

SB 339 previously passed the Senate on May 7. It now heads to Gov. Greg Abbott.

“On a certain level, the legislature should be commended for acknowledging the medical value of marijuana, and it is an historic vote in that sense,” said Heather Fazio, Texas political director for the Marijuana Policy Project (MPP). “Lawmakers missed several opportunities to amend the bill in ways that could have provided real relief to countless Texans. Not a single patient will be helped by this legislation.”

SB 339 requires doctors to “prescribe” marijuana to patients, which exposes doctors to federal criminal sanctions. By contrast, doctors “recommend” medical marijuana or “certify” patients to use medical marijuana in the 23 states with comprehensive medical marijuana laws and the District of Columbia. Unlike “prescriptions,” recommendations and certifications are federally legal and protected under the First Amendment.

Illinois: Desktop Cannabis Potency Measurement System To Be Unveiled At Marijuana Business Expo

LuminarySageAnalytics

Sage Analytics, developers of portable laboratory quality cannabis potency measurement systems, on Wednesday announced that they will introduce their newest product, the Luminary™ Beacon, at the Marijuana Business Conference and Expo, to be held in Chicago, May 19-21.

Unlike any other product on the market, according to Sage, "the Beacon provides instant, on-the-spot feedback, and is expected to be a vital tool toward standardization in cannabis potency profiling, and accuracy in consumer information and labeling."

"The Luminary™ Beacon is a small, portable desktop system that is simple to use in any location and requires little training to obtain on-site, instantaneous, laboratory-grade accurate measurement of THC, CBD, and CBN," the company's press release states. "Unlike gas chromatography (GC) or high performance liquid chromatography (HPLC), the Luminary™ Beacon uses optical spectroscopy (light) to instantly measure the potency of cannabis products at the molecular level.

Spectroscopy offers a number of distinct advantages over alternative methods, according to Sage Analytics: It is portable and can be used virtually anywhere, it is easy to use and requires just minimal training to become proficient, requires no toxic chemicals for preparation or analysis, and it leaves the sample intact for future use.

Texas: Senate Approves Unworkable Medical Marijuana Bill

TexasMedicalMarijuanaPolicyReform[ProgressTexas]

House will now consider measure that is intended to allow access to low-THC marijuana extract for qualifying seizure patients

The Texas State Senate on Thursday approved a bill 26-5 that is intended to allow qualifying patients with intractable seizure conditions to access a marijuana extract containing high levels of cannabidiol, or CBD, and only trace levels of THC. SB 339, introduced by Sen. Kevin Eltife (R-Tyler), will now be considered by the state House of Representatives.

“We’re pleased to see a majority of the Senate recognizes the medical benefits of marijuana, but it’s of little comfort if patients aren’t able to experience them,” said Heather Fazio, Texas political director for the Marijuana Policy Project (MPP). “Texas needs a comprehensive medical marijuana program that allows patients to take full advantage of the various compounds found in different types of marijuana.”

SB 336 requires doctors to “prescribe” marijuana to patients, which exposes doctors to federal criminal sanctions. By contrast, doctors “recommend” medical marijuana or “certify” patients to use medical marijuana in the 23 states with comprehensive medical marijuana laws and the District of Columbia.

Unlike “prescriptions,” recommendations and certifications are federally legal and protected under the First Amendment.

California: Twyns CBD and THC Mixing Kit Introduced

HempHealthTwyns2-PackCBD-THC

Created for creating a personalized, therapeutic blend of liquid Cannabidiol and THC, the makes of Twyns say it helps people make the best use of cannabis for personal health and wellness

Hemp Health Inc., maker of hemp cannabidiol (CBD) products, on Tuesday released Pharma-CBD Twyns, which the company describes in a press release as "the first legal CBD and THC mixing kit."

Designed for sale at medical marijuana dispensaries, Twyns allows cannabis users to create a therapeutic blend of CBD and THC – without smoking anything.

Twyns will help patients and everyday users personalize cannabis supplementation to meet their health and wellness goals, according to the company.

THC (Tetrahydrocannabinol) is a principal compound in medical marijuana, and while patients normally get THC by smoking the plant, this presents three problems.

First, many patients would prefer not to smoke. Second, most medical marijuana is rich in THC but very low in CBD. Third, individuals react differently to various levels of CBD and THC, but normally they can't choose the proportion of each compound.

According the Hemp Health, Twyns addresses all three problems by allowing users to ingest THC and custom blend both compounds in one liquid solution.

"Twyns" refers to the two bottles contained in the mixing kit. One bottle comes filled with Hemp Health Inc.'s pharma-grade CBD. The second bottle is for liquid THC, and law requires that it be filled by a local dispensary.

Canada: CannTrust Launches New Line of Patient Ready Medical Marijuana Strains

CannTrust-QualityCannabisYouCanTrust.PharmacistControlledAndOperated

CannTrust develops new line of products in a ready to use format at $3.50/gram

CannTrust, "Canada's only pharmacist-controlled and operated producer of medical cannabis," has launched of its own product line of "patient ready strains" at just $3.50 a gram, delivered. "Patient ready," in this context, means that the weed arrives in a pre-ground state, ready for your vaporizer, pipe, bong or paper.

"We are pleased to offer this new format of products carefully selected from our most popular strains of premium cannabis," reads a prepared statement from the company. "The cannabis is from the same harvest and lots as the original bud form of these same strains and is then refined into an already prepared version of medical cannabis that is easy to use by patients, especially in a vaporizer."

"We are very excited about the launch of these products for several reasons that we feel will be beneficial to both patients and their doctors," the company announced.

Each of the three strains are only $3.50/gram, "making this an affordable and easy to use option for medical cannabis," the company announced.

Supreme Formula - Patient Ready
THC: 8.5% • CBD: 0.2%
Indica/Sativa Hybrid
Supreme Formula 8.5 percent THC is a unique blend of the best THC strains. This was specially formulated to meet the recommendations of the College of Family Physicians of Canada's recommendation of up to 9 percent THC, according to CannTrust.

Original Cheese - Patient Ready
THC: 11.4% • CBD: 0.1%
Indica 50% • Sativa 50%

Ohio: New Video Tells Story of Young Epilepsy Patient Without Safe Access To Medical Marijuana

SophiasStory

Moving Video Features Struggle and Frustration of Ohio Family That Has Run Out of Treatment Options for Their Daughter

The Drug Policy Alliance and Learn Liberty have teamed up to tell the emotional story of Sophia Nazzarine, a 7-year-old girl suffering from uncontrolled epilepsy, in a new video.

Between clips of Sophia singing and playing with her parents in her hometown of Cincinnati, the audience is shown saddening footage of Sophia seizing as a newborn, while her parents describe their discovery of Sophia’s epilepsy and their exhaustive struggle to find an effective treatment.

“We’ve tried everything else that they could possibly come up with to try and stop these seizures,” says Scott Nazzarine, Sophia’s father. “None of it has worked. We need legislation that allows our child to get the medicine she needs. But with or without it, we will continue to give our child what she needs to reduce her dangerous seizures.”

Sophia’s story is complemented by interviews with doctors, explaining her condition and the strong potential for its treatment with marijuana.

“The belief is that it’s the cannabidiol portion of [the marijuana plant] that seems to have less intoxicating effects and more of the anti-seizure effects,” explained Dr. Michael D. Privitera, professor of Neurology at the University of Cincinnati.

Syndicate content